CHANGE IN RATINGS
upgraded at Cantor Fitzgeraldto Buy. Push into miRNA therapeutics with Isis should help drive future growth. $32 price target.
Dolan Media Group
coverage initiated at Goldman Sachs with a Neutral rating. See attractive business mix, leverage to mortgage loan foreclosures, and strong operating momentum. However, stock's performance since August 1 IPO leave shares fully valued. Price target at $22.
initiated at Morgan Stanley with an overweight rating and $20 price target.
upgraded at Bear Stearnsto Outperform. $63 price target. Company posted positive performance in the Flex trial, which has $1 billion annual sales potential for the treatment of non-small cell lung cancer.
upgraded at Deutsche Bank from Hold to Buy. $9 price target. Stock has dropped 38% since the AGR purchase, and business likely bottomed in the second quarter.
downgraded at Merrill Lynchfrom Neutral to Sell. 2008 estimates also cut, based on lower housing expectations. Investors should look to switch out for TXI.
Goldman is reinstating its Buy rating on
( PDE) following the divestiture of the company's Latin American business. See assets as undervalued and believe company is an attractive acquisition target. Also bullish on deep water fundamentals. Price target at $43.
upgraded at Goldman from Neutral to Buy. The company trades at a market discount and industry fundamentals should continue to improve heading into 2008.
upgraded at Keybanc from Underweight to Hold. Company appears to be on the right strategy with its repositioning strategy.
( TMA) upgraded at UBS to Buy rating from Neutral. Price target and FY2008 eps estimates lowered to $18 from $27 and to ($5.26) from $2.59, respectively.
downgraded at Friedman, Billings Ramsey from Outperform to Market Perform. Stock is up 60% since June, approaching the $36 price target, and is already pricing in a solid third quarter.
upgraded at Bear Stearns from Peer Perform to Outperform. Estimates also raised, to reflect improving industry conditions. $32 price target.
STOCK COMMENTS / EPS CHANGES
numbers lowered at Jefferies. Price target drops to $15 from $19 and FY 2008 eps estimates lowered to $0.60 from $0.73. Reiterates Hold rating.
( TLAB) numbers lowered at UBS. Price target drops to $11.50 from $14 and FY 2008 eps estimates holds at $0.44. Reiterates Neutral rating.
STRATEGY CALLS / MARKET CALLS
Beverage sector upgraded at Goldman Sachs to Attractive due to higher expectations for 2008 earnings and macroeconomic conditions. See more benign commodity costs, low-to-mid teens overseas profit growth for the group, better-than-expected U.S. beer demand, and median historic valuation. Upgraded
to Buy from Neutral in conjunction with sector upgrade.
are other top picks.